Some cellular signaling pathways, including CSCs (cancer stem cells), the Notch pathway, the EMT (epithelial-mesenchymal transition) and mTOR (mammalian target Rapamycin) can affect the antitumor activity of molecular targeting agents (34–40). The gene discussed is MTOR; the disease is cancer.